Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 8/20 | 0.50 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 6/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.43 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL823178 | 0.90 | TLR7 (0.50) | TLR7NUDT1CTSLKDM4EALDH1A1 | |
| SCHEMBL823231 | 0.82 | CDK1 (0.48) | CTSLADORA2AADORA1TMIGD3ADORA2B | |
| SCHEMBL822925 | 0.81 | TLR7 (0.60) | TLR7NUDT1ADORA2AADORA1 | |
| SCHEMBL509587 | 0.76 | TLR7 (0.74) | TLR7NUDT1ADORA2AADORA1 | |
| SCHEMBL2058803 | 0.75 | TLR7 (0.56) | TLR7NUDT1 | |
| SCHEMBL21759512 | 0.71 | HRH4 (0.39) | TLR7KDM4EALDH1A1 | |
| SCHEMBL12175835 | 0.71 | TLR7 (0.64) | TLR7NUDT1 | |
| SCHEMBL21449006 | 0.70 | TLR7 (0.54) | TLR7 | |
| SCHEMBL43087 | 0.70 | TLR7 (0.60) | TLR7NUDT1 | |
| SCHEMBL2058924 | 0.70 | TLR7 (0.60) | TLR7NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009247-A1 | PHOSPHOLIPID DRUG ANALOGS | BIOPHARMA CREDIT PLC (GB) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009247-A1 | PHOSPHOLIPID DRUG ANALOGS | PHOSPHO1, PXMP4, SGMS1 | TLR7 1935/4885NUDT1 1425/4885CTSL 4404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.